New centres to carry out more clinical trials in Norway

Inger Marie Skoie, researcher and senior consultant at the Department of Dermatology, Stavanger University Hospital, and head of the NorTrials Inflammation Centre.

The author has completed the ICMJE form and declares the following conflicts of interest: Participated in advisory groups and held lectures for Novartis, Eli-Lilly, Janssen, AbbVie and Pfizer.

Jan Gunnar Skogås, medical technology background, CEO and head of department for the Operating Room of the Future research infrastructure at St. Olavs Hospital, Trondheim University Hospital/Norwegian University of Science and Technology, head of the NorTrials Medical Devices Centre, head of the NorMIT (Norwegian Centre for Minimally Invasive Image Guided Therapy and Medical Technologies) national infrastructure, and clinical director and head of department at Røros Hospital – St. Olavs Hospital, Trondheim University Hospital.

The author has completed the ICMJE form and declares no conflicts of interest.

Thomas Langø, senior researcher at St. Olavs Hospital, Trondheim University Hospital and SINTEF (Medical Technology research group), medical director of the NorTrials Medical Devices Centre and the Norwegian National Advisory Unit for Ultrasound and Image-Guided Therapy. Member of the National Committee for Medical and Health Research Ethics and the board of advisors for The Operating Room of the Future, Research Department, St. Olavs Hospital, Trondheim University Hospital.

The author has completed the ICMJE form and declares no conflicts of interest.

Kjell-Morten Myhr, professor at the University of Bergen and senior consultant, Department of Neurology, Haukeland University Hospital. Head of Neuro-SysMed and the NorTrials Brain Health Centre. Member of the board of advisors for the Multiple Sclerosis Association and the group of MS specialists in Sykehusinnkjøp (the Norwegian Hospital Procurement Trust), and head of the working group that prepared the national clinical guidelines for diagnostics and treatment of multiple sclerosis.

The author has completed the ICMJE form and declares the following conflicts of interest: Received lecture fees from Biogen, Merck, Novartis, Roche and Sanofi, and participated in clinical trials organised by Biogen, Merck, Novartis, Otivio, Roche and Sanofi.

Peder Langeland Myhre, associate professor at the University of Oslo and acting senior consultant at the Department of Cardiology, Akershus University Hospital. Head of the NorTrials Cardiovascular Centre and deputy head of the working group for heart failure, Norwegian Cardiological Society, and editor of the Hjerteforum journal.

The author has completed the ICMJE form and declares the following conflicts of interest: Participated in clinical trials by and/or received lecture fees from Amarin, AstraZeneca, AmGen, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Novartis and Novo Nordisk.

Rasmus Goll, associate professor, head of the Gastroenterology and Nutrition Research Group at the University of Tromsø, Arctic University of Norway, and senior consultant at the Medical Department, University Hospital of North Norway. Head of the NorTrials Gastrointestinal Centre, head of the Northern Norway Regional Committee for Medical and Health Research, and head of the Gastroenterological Society of Northern Norway.

The author has completed the ICMJE form and declares no conflicts of interest.

Signe Øien Fretland, cand.pharm. Engaged in the start-up and coordination of clinical trials in the pharmaceutical industry and at Oslo University Hospital. Since 2022, head of the NorTrials coordinating unit, which is the operational component of the programme.

The author has completed the ICMJE form and declares no conflicts of interest.

Åslaug Helland, specialist in oncology, research director at the Cancer Clinic, Oslo University Hospital, professor at the University of Oslo and head of the NorTrials Cancer Centre.

The author has completed the ICMJE form and declares the following conflicts of interest: Has held lectures for and participated in advisory meetings with AbbVie, Takeda, AstraZeneca, Roche, Pfizer, Janssen, Eli Lilly, Bristol-Myers Squibb, Pierre Fabre, Bayer, MSD, Novartis, Merck and Sanofi, for which any fees have gone to Oslo University Hospital. Has received grants for self-initiated research from Roche, AstraZeneca, Novartis, Incyte, Eli Lilly, Bristol-Myers Squibb, Ultimovacs and Illumina.